About Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: N/A
- Symbol: NYSE:TEVA
- CUSIP: N/A
- Web: www.tevapharm.com
- Market Cap: $30.36 billion
- Outstanding Shares: 1,016,000,000
- 50 Day Moving Avg: $31.48
- 200 Day Moving Avg: $34.62
- 52 Week Range: $29.46 - $56.44
Sales & Book Value:
- Trailing P/E Ratio: 383.08
- Foreward P/E Ratio: 6.30
- P/E Growth: 2.18
- Annual Revenue: $22.72 billion
- Price / Sales: 1.34
- Book Value: $29.92 per share
- Price / Book: 1.00
- Annual Dividend: $1.16
- Dividend Yield: 4.5%
- EBIDTA: $7.32 billion
- Net Margins: 1.50%
- Return on Equity: 17.46%
- Return on Assets: 7.32%
- Debt-to-Equity Ratio: 0.99%
- Current Ratio: 0.90%
- Quick Ratio: 0.62%
- Average Volume: 6.96 million shs.
- Beta: 0.58
- Short Ratio: 2.43
Frequently Asked Questions for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
What is Teva Pharmaceutical Industries Ltd's stock symbol?
Teva Pharmaceutical Industries Ltd trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."
How often does Teva Pharmaceutical Industries Ltd pay dividends? What is the dividend yield for Teva Pharmaceutical Industries Ltd?
Teva Pharmaceutical Industries Ltd announced a quarterly dividend on Thursday, May 11th. Stockholders of record on Monday, June 5th will be given a dividend of $0.34 per share on Thursday, June 22nd. This represents a $1.36 annualized dividend and a dividend yield of 4.55%. The ex-dividend date of this dividend is Thursday, June 1st. View Teva Pharmaceutical Industries Ltd's Dividend History.
How were Teva Pharmaceutical Industries Ltd's earnings last quarter?
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) released its earnings results on Thursday, May, 11th. The company reported $1.06 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.06. The business earned $5.63 billion during the quarter, compared to analysts' expectations of $5.69 billion. Teva Pharmaceutical Industries Ltd had a return on equity of 17.46% and a net margin of 1.50%. The company's quarterly revenue was up 17.0% compared to the same quarter last year. During the same period last year, the business posted $1.20 earnings per share. View Teva Pharmaceutical Industries Ltd's Earnings History.
What guidance has Teva Pharmaceutical Industries Ltd issued on next quarter's earnings?
Teva Pharmaceutical Industries Ltd issued an update on its FY17 earnings guidance on Thursday, May, 11th. The company provided EPS guidance of $4.90-5.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.81. The company issued revenue guidance of $23.8-24.5 billion, compared to the consensus revenue estimate of $23.67 billion.
Where is Teva Pharmaceutical Industries Ltd's stock going? Where will Teva Pharmaceutical Industries Ltd's stock price be in 2017?
25 brokers have issued twelve-month target prices for Teva Pharmaceutical Industries Ltd's stock. Their predictions range from $27.00 to $80.00. On average, they expect Teva Pharmaceutical Industries Ltd's share price to reach $44.52 in the next year. View Analyst Ratings for Teva Pharmaceutical Industries Ltd.
What are analysts saying about Teva Pharmaceutical Industries Ltd stock?
Here are some recent quotes from research analysts about Teva Pharmaceutical Industries Ltd stock:
- 1. According to Zacks Investment Research, "The Actavis Generics acquisition helped Teva strengthen its position in the key generic markets. Teva continues to progress with its branded and generics drugs pipeline and is looking to strengthen its biosimilar pipeline. Meanwhile, Teva intends to accelerate growth platforms, protect and expand core franchises, expand its global presence, pursue strategic deals and reduce the cost base. However, headwinds remain in the form of generic competition for Copaxone, new competition for branded products, fewer large generic opportunities, generic pricing pressure, a higher cost base and debt level and the sudden departure of its chief executive office. Also, Teva’s shares underperformed the generic industry in the past one year. Estimate movement has been mixed ahead of the company’s Q1 earnings release. The company has a positive record of earnings surprises in recent quarters. " (4/17/2017)
- 2. Maxim Group analysts commented, "We reviewed and revised our model prior to the 1Q17 earnings release. Based on 2017 guidance and our expectations, we adjust OTC revenues in 1Q17 to $277M from $346M to reflect the change in foreign exchange rate as of December 1, 2016. Our estimate for total 2017 revenues is unchanged at $24B." (3/29/2017)
- 3. Royal Bank of Canada analysts commented, "TEVA reported 4Q above Street expectations and reaffirmed 2017 guidance with some further color around the year. The bull case in TEVA lacks conviction and change is needed. We look to CEO search/ strategic review, potential for break-up, and potential upside from generic Copaxone surprise as opportunity but near-term confidence remains low. No change to PT but EPS moves lower to reflect greater competitive pressures." (2/14/2017)
Who are some of Teva Pharmaceutical Industries Ltd's key competitors?
Some companies that are related to Teva Pharmaceutical Industries Ltd include Dr.Reddy's Laboratories Ltd (RDY), United Therapeutics (UTHR), Ionis Pharmaceuticals (IONS), Endo International plc - (ENDP), Synergy Pharmaceuticals (SGYP), Amarin Co. plc (AMRN), Amphastar Pharmaceuticals (AMPH), Depomed (DEPO), Sucampo Pharmaceuticals (SCMP), SciClone Pharmaceuticals (SCLN), DURECT (DRRX), Summit Therapeutics PLC (SMMT), Albireo Pharma (ALBO), Merus Labs International (MSLI), Cardiome Pharma Corp (CRME), Cumberland Pharmaceuticals (CPIX), Aralez Pharmaceuticals (ARLZ) and MEI Pharma (MEIP).
Who owns Teva Pharmaceutical Industries Ltd stock?
Teva Pharmaceutical Industries Ltd's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (3.62%), Barrow Hanley Mewhinney & Strauss LLC (2.93%), Bank of New York Mellon Corp (1.91%), Nordea Investment Management AB (1.24%), Paulson & CO. Inc. (1.08%) and Alliancebernstein L.P. (0.85%). View Institutional Ownership Trends for Teva Pharmaceutical Industries Ltd.
Who sold Teva Pharmaceutical Industries Ltd stock? Who is selling Teva Pharmaceutical Industries Ltd stock?
Teva Pharmaceutical Industries Ltd's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Lazard Asset Management LLC, Paulson & CO. Inc., Henderson Group PLC, Janus Capital Management LLC, Barrow Hanley Mewhinney & Strauss LLC, Waddell & Reed Financial Inc. and NN Investment Partners Holdings N.V.. View Insider Buying and Selling for Teva Pharmaceutical Industries Ltd.
Who bought Teva Pharmaceutical Industries Ltd stock? Who is buying Teva Pharmaceutical Industries Ltd stock?
Teva Pharmaceutical Industries Ltd's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Harel Insurance Investments & Financial Services Ltd., Ameriprise Financial Inc., Commerzbank Aktiengesellschaft FI, Private Management Group Inc., State Street Corp, Alliancebernstein L.P. and Camber Capital Management LLC. View Insider Buying and Selling for Teva Pharmaceutical Industries Ltd.
How do I buy Teva Pharmaceutical Industries Ltd stock?
Shares of Teva Pharmaceutical Industries Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Teva Pharmaceutical Industries Ltd stock cost?
One share of Teva Pharmaceutical Industries Ltd stock can currently be purchased for approximately $29.88.
Earnings History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)Earnings History by Quarter for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/11/2017||Q1 17||$1.06||$1.06||$5.69 billion||$5.63 billion||View||N/A|
|2/13/2017||Q416||$1.36||$1.38||$6.26 billion||$6.25 billion||View||N/A|
|11/15/2016||Q316||$1.29||$1.31||$5.71 billion||$5.56 billion||View||N/A|
|8/4/2016||Q216||$1.20||$1.25||$4.86 billion||$5.00 billion||View||N/A|
|5/9/2016||Q116||$1.17||$1.20||$4.78 billion||$4.81 billion||View||N/A|
|2/11/2016||Q415||$1.29||$1.28||$4.83 billion||$4.88 billion||View||Listen|
|10/29/2015||Q315||$1.28||$1.35||$4.75 billion||$4.80 billion||View||Listen|
|7/30/2015||Q215||$1.31||$1.43||$4.90 billion||$4.97 billion||View||Listen|
|4/30/2015||Q115||$1.26||$1.36||$4.84 billion||$5.00 billion||View||N/A|
|2/5/2015||Q414||$1.31||$1.31||$5.17 billion||$5.17 billion||View||N/A|
|10/30/2014||Q314||$1.23||$1.32||$5.09 billion||$5.06 billion||View||N/A|
|7/31/2014||Q214||$1.21||$1.23||$5.08 billion||$5.00 billion||View||N/A|
|5/1/2014||Q114||$1.22||$1.22||$5.11 million||$5.00 billion||View||N/A|
|2/6/2014||Q413||$1.26||$1.42||$5.19 billion||$5.40 billion||View||N/A|
|10/31/2013||Q313||$1.26||$1.27||$5.00 billion||$5.06 billion||View||N/A|
|8/1/2013||Q213||$1.20||$1.20||$4.94 billion||$4.90 billion||View||N/A|
|5/2/2013||Q113||$1.10||$1.12||$4.85 billion||$4.90 billion||View||N/A|
|2/7/2013||Q412||$1.33||$1.32||$5.26 billion||$5.20 billion||View||N/A|
|11/1/2012||Q312||$1.25||$1.28||$5.08 billion||$5.00 billion||View||N/A|
Earnings Estimates for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Current Year EPS Consensus Estimate: $4.81 EPS
Next Year EPS Consensus Estimate: $4.74 EPS
Current Dividend Information for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
|Dividend Growth:||2.10% (3 Year Average)|
|Payout Ratio:||1,657.38% (Trailing 12 Months of Earnings) |
24.12% (Based on This Year's Estimates)
24.47% (Based on Next Year's Estimates)
Dividend History by Quarter for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Latest Headlines for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Teva Pharmaceutical Industries Ltd (TEVA) Chart for Monday, May, 22, 2017